Cardiac Structural Complications Following TAVR

Circ Cardiovasc Interv. 2026 Feb 5:e015991. doi: 10.1161/CIRCINTERVENTIONS.125.015991. Online ahead of print.ABSTRACTBACKGROUND: Cardiac structural complications (CSCs) have been recently established by the Valve Academic Research Consortium 3 consensus as a combined end point including multiple lif

S Silvia Mas-Peiro

Optimizing the management of congenital thrombotic thrombocytopenic purpura

Res Pract Thromb Haemost. 2026 Jan 20;9(Suppl 4):103270. doi: 10.1016/j.rpth.2025.103270. eCollection 2025 Dec.ABSTRACTBACKGROUND: Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare, life-threatening thrombotic microangiopathy caused by genetic mutations in the ADAMTS-13 gene, leading t

M Melissa F Glasner

Raspberry protective role in inflammatory diseases: An overview

Iran J Basic Med Sci. 2026;29(1):22-33. doi: 10.22038/ijbms.2025.89042.19218.ABSTRACTInflammation is a natural immune response triggered by multiple factors such as pathogens, damaged cells, and toxic substances. These triggers can lead to both acute and chronic inflammatory reactions in different t

P Priyanka Arya

Glycosylation Profiles in Cardiovascular Diseases: A Bibliometric Analysis

Health Data Sci. 2026 Feb 3;6:0409. doi: 10.34133/hds.0409. eCollection 2026.ABSTRACTBackground: Cardiovascular diseases (CVDs) continue to be the leading cause of morbidity and mortality globally, indicating a major global health burden. Glycosylation, one of the key posttranslational modifications

T Tianqi Chang